share_log

Portage Biotech Analyst Ratings

Benzinga Analyst Ratings ·  Nov 30, 2022 20:21
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
11/30/2022 202.01% Oppenheimer $26 → $18 Maintains Outperform
09/20/2022 269.13% HC Wainwright & Co. $32 → $22 Maintains Buy
03/07/2022 436.91% HC Wainwright & Co. → $32 Initiates Coverage On → Buy
09/21/2021 403.36% Oppenheimer → $30 Initiates Coverage On → Outperform
09/02/2021 571.14% B. Riley Securities → $40 Initiates Coverage On → Buy
08/19/2021 487.25% Cantor Fitzgerald → $35 Initiates Coverage On → Overweight

What is the target price for Portage Biotech (PRTG)?

The latest price target for Portage Biotech (NASDAQ: PRTG) was reported by Oppenheimer on November 30, 2022. The analyst firm set a price target for $18.00 expecting PRTG to rise to within 12 months (a possible 202.01% upside). 3 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Portage Biotech (PRTG)?

The latest analyst rating for Portage Biotech (NASDAQ: PRTG) was provided by Oppenheimer, and Portage Biotech maintained their outperform rating.

When is the next analyst rating going to be posted or updated for Portage Biotech (PRTG)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Portage Biotech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Portage Biotech was filed on November 30, 2022 so you should expect the next rating to be made available sometime around November 30, 2023.

Is the Analyst Rating Portage Biotech (PRTG) correct?

While ratings are subjective and will change, the latest Portage Biotech (PRTG) rating was a maintained with a price target of $26.00 to $18.00. The current price Portage Biotech (PRTG) is trading at is $5.96, which is out of the analyst's predicted range.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment